Please assess the completion status of the following clinical trial:

Trial Title: Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years of age or older~* Histologically confirmed Glioblastoma Multiforme (GBM)~* Radiographic evidence of disease progression~* Patients must have evaluable contrast enhancing tumor~* Availability of paraffin blocks or unstained pathology slides for biomarker studies~* Karnofsky Performance Status of greater than or equal to 60%~Exclusion Criteria:~* Prior treatment with Mammalian target of rapamycin (mTOR) inhibitor~* History of another malignancy within 3 years~* Cardiac pacemaker~* Ferromagnetic metal implants other than those approves as safe for use in Magnetic resonance imaging (MRI) scanners~* Claustrophobia~* Obesity~* Unstable systemic diseases~* Elevated cholesterol or triglycerides~* Radiation therapy or cytotoxic chemotherapy \<=4 weeks prior to study enrollment. Patient must have recovered from the toxic effects of a prior chemotherapy.~* Patients must be off all enzyme inducing anticonvulsants for at least 2 week before study enrollment can occur~* Need for increasing dose of steroids. Patients on a stable or tapering dose of steroids \>=7 days were permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Surgery (Everolimus 10 mg) (Type: EXPERIMENTAL): Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
- Everolimus 10 mg + Surgery (Type: EXPERIMENTAL): Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
- Everolimus 5 mg + Surgery (Type: EXPERIMENTAL): Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
- Everolimus 0 mg + Surgery (Type: ACTIVE_COMPARATOR): Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).